pSivida Corp. announced that Finland and Luxembourg have granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. This brings the total number of EU countries in which ILUVIEN has been approved to 15, with two EU approvals still pending.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.67 USD | -8.25% | +11.28% | -58.16% |
06-26 | EyePoint Pharmaceuticals, Inc. Highlights Duravuyu Clinical and Regulatory Progress and Pipeline Innovation At R&D Day 2024 | CI |
06-26 | Transcript : EyePoint Pharmaceuticals, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.16% | 504M | |
+55.35% | 815B | |
+32.37% | 597B | |
-0.10% | 377B | |
+15.47% | 319B | |
+13.10% | 310B | |
+16.32% | 247B | |
+15.08% | 228B | |
+16.54% | 180B | |
+4.31% | 170B |
- Stock Market
- Equities
- EYPT Stock
- News EyePoint Pharmaceuticals, Inc.
- PSivida Corp. ILUVIEN Receives Marketing Authorization in Two More EU Countries